Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] /
Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.
Main Authors: | , , |
---|---|
Format: | Texto biblioteca |
Language: | eng |
Published: |
Boston, MA : Springer US : Imprint: Springer,
2002
|
Subjects: | Medicine., Cancer research., Oncology., Medicine & Public Health., Cancer Research., |
Online Access: | http://dx.doi.org/10.1007/978-1-4615-1173-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
KOHA-OAI-TEST:206808 |
---|---|
record_format |
koha |
spelling |
KOHA-OAI-TEST:2068082018-07-30T23:36:37ZClinically Relevant Resistance in Cancer Chemotherapy [electronic resource] / Andersson, Borje. editor. Murray, David. editor. SpringerLink (Online service) textBoston, MA : Springer US : Imprint: Springer,2002.engOver the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.Medicine.Cancer research.Oncology.Medicine & Public Health.Oncology.Cancer Research.Springer eBookshttp://dx.doi.org/10.1007/978-1-4615-1173-1URN:ISBN:9781461511731 |
institution |
COLPOS |
collection |
Koha |
country |
México |
countrycode |
MX |
component |
Bibliográfico |
access |
En linea En linea |
databasecode |
cat-colpos |
tag |
biblioteca |
region |
America del Norte |
libraryname |
Departamento de documentación y biblioteca de COLPOS |
language |
eng |
topic |
Medicine. Cancer research. Oncology. Medicine & Public Health. Oncology. Cancer Research. Medicine. Cancer research. Oncology. Medicine & Public Health. Oncology. Cancer Research. |
spellingShingle |
Medicine. Cancer research. Oncology. Medicine & Public Health. Oncology. Cancer Research. Medicine. Cancer research. Oncology. Medicine & Public Health. Oncology. Cancer Research. Andersson, Borje. editor. Murray, David. editor. SpringerLink (Online service) Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] / |
description |
Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge. |
format |
Texto |
topic_facet |
Medicine. Cancer research. Oncology. Medicine & Public Health. Oncology. Cancer Research. |
author |
Andersson, Borje. editor. Murray, David. editor. SpringerLink (Online service) |
author_facet |
Andersson, Borje. editor. Murray, David. editor. SpringerLink (Online service) |
author_sort |
Andersson, Borje. editor. |
title |
Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] / |
title_short |
Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] / |
title_full |
Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] / |
title_fullStr |
Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] / |
title_full_unstemmed |
Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] / |
title_sort |
clinically relevant resistance in cancer chemotherapy [electronic resource] / |
publisher |
Boston, MA : Springer US : Imprint: Springer, |
publishDate |
2002 |
url |
http://dx.doi.org/10.1007/978-1-4615-1173-1 |
work_keys_str_mv |
AT anderssonborjeeditor clinicallyrelevantresistanceincancerchemotherapyelectronicresource AT murraydavideditor clinicallyrelevantresistanceincancerchemotherapyelectronicresource AT springerlinkonlineservice clinicallyrelevantresistanceincancerchemotherapyelectronicresource |
_version_ |
1756268299096686592 |